Clinical Trial

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 alone in subjects with advanced digestive system neoplasms.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-30.
Status change: Not Yet Recruiting → Recruiting 2023-09-08
Trial Details
NCT Number NCT06019702
Lead Sponsor Sir Run Run Shaw Hospital
Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions Digestive System Neoplasms
Enrollment 20 participants
Start Date 2023-09-08
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-09-11